Clinical Trial Update: Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities [Phase 3]

View source ↗

Summary

Phase 3 trial updated on the efficacy and safety of rivaroxaban to reduce major thrombotic vascular events in patients with symptomatic peripheral artery diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Artery Disease

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Peripheral Artery Disease | Phase 3 | Status: COMPLETED | Results posted: 2020-12-08